High Demand & A Global Shortage… Investors Should Be Watching This Niche Gas on 07/13/2021. Learn More

Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Alphatec Shares Rise After Firm Announces Strong Organic Revenue Growth in Q2

Share on Stocktwits


Alphatec Holdings Inc. shares traded 12% higher after the company reported preliminary Q2/21 financial results that included a larger than 90% increase in YoY organic revenue.

Medical technology company Alphatec Holdings Inc. (ATEC:NASDAQ), which is focused on designing, developing, manufacturing and selling products for surgically treating spine disorders, today announced select preliminary revenue data for Q2/21 ended June 30, 2021.

Alphatec Holdings advised that on a preliminary basis, U.S. organic revenue in Q2/21 is expected to increase to between $55.4 and 56.0 million, representing an increase of 92.1-94.2% compared to Q2/20.

During the same corresponding period, the company indicated that it expects total revenue will increase by 88.2-90.2% to $55.80-56.4 million. The firm noted that each of these preliminary estimates exclude the impact of EOS imaging on operations,

The company stated that as of the end of the quarter on June 30, 2021, it had approximately $74.0 million in cash on its balance sheet and another $40.0 million available if needed on its existing term loan.

The firm noted that it intends to report it full Q2/21 financial results and FY/21 revenue guidance after the close of U.S. markets on August 3, 2021. The company stated that at that time it will incorporate the data from its EOS imaging acquisition into the full-year estimates.

Alphatec Holdings' Chairman and CEO Pat Miles commented, "Portfolio-wide momentum is driving aggressive U.S. revenue growth and gives us confidence that organic U.S. revenue growth will exceed 50% this year…The spine prowess we are building has clearly begun to deliver, but we are just getting started. The PTP technique is gaining momentum and can not only penetrate, but more importantly, expand the minimally invasive market for spine. Our increasingly competitive portfolio is enabling us to capture more of each procedural opportunity, and we have vast potential to continue to grow ATEC's U.S. footprint."

"We also just closed the EOS imaging transaction, which will bring unprecedented clinical information into the O.R. and extend our reach into EOS' high-caliber account base. ATEC is exceptionally well-positioned to continue to earn surgeon confidence and market share," Miles added.

The company reiterated that the preliminary unaudited financial results released today are based upon the firm's present expectations and may be adjusted somewhat after customary quarter-end close financial and procedural reviews.

The firm stated additionally that for FY/21, it expects that U.S. organic revenue growth will exceed 50%.

Alphatec, based in Carlsbad, Calif., which operates primarily through two "wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction."

Alphatec Holdings started the day with a market cap of around $1.4 billion with approximately 97.5 million shares outstanding and a short interest of about 2.2%. ATEC shares opened nearly 14% higher today at $16.11 (+$1.96, +13.85%) over Friday's $14.15 closing price. The stock has traded today between $15.47 and $16.47 per share and is currently trading at $15.91 (+$1.76, +12.44%).


1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe